Paratek Pharmaceuticals

At Paratek Pharmaceuticals, our customers, the patients with infectious diseases and other difficult-to-treat conditions, are at the heart of everything we do. We understand the critical challenges they face, particularly with the growing threat of antimicrobial resistance (AMR), a global public health issue that renders common infections life-threatening. This is why we are passionately committed to developing and commercializing transformative solutions. Our primary goal is to create positive patient stories and outcomes by providing innovative therapies. We believe that by combining the right people, the right knowledge, and the right drugs, we can make a significant difference in the lives of patients, their physicians, and their caregivers. Our work is driven by a deep sense of purpose and integrity, turning everyday decisions into triumphs that advance our technology and strengthen our company.

Our leading product, NUZYRA® (omadacycline), is a testament to our customer-centric approach. It is an FDA-approved, once-daily antibiotic available in both oral and intravenous formulations, designed to address the urgent unmet needs of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Recognizing the challenges healthcare providers face in treating these serious infections, we developed NUZYRA to be a powerful tool against a wide range of susceptible bacteria. We are also dedicated to expanding our impact by addressing other public health threats and have secured a contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for pulmonary anthrax. Our vision is to be a leading biopharmaceutical company, and we are continuously working to build a portfolio of life-saving products for those who need them most, ensuring that patients have access to the effective treatments they deserve.